Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TNXP Strong volume for tomorrow
SLRX Golden Cross Chart
SLRX Strong Bullish patterns
Chart: http://schrts.co/NXUkQqad
Good Morning to all!
AXAS Oil Stock with Bullish Pattern!
Chart: http://schrts.co/UiUazjEv
SLRX The BEST Chart of The market...
Chart: http://schrts.co/UvrNHhuW
SLRX Golden Cross according Chart
Chart: https://schrts.co/GBWGXIRt
$TTNP first PT $5
GM augusta
POSITIVE EARLY STUDY RESULTS HELP PAVE WAVE FOR TITAN PHARMACEUTICALS TO MOVE FORWARD WITH ITS JT-09 PRONEURA® DEVELOPMENT PROGRAM
February 01, 2021
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ --
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for the human kappa-opioid receptor ("KOR"). JT-09 is being developed for use in combination with Titan's ProNeura® long-term, continuous drug delivery technology for the treatment of moderate-to-severe chronic pruritus (itch).
Titan Pharmaceuticals, Inc. (PRNewsfoto/Titan Pharmaceuticals, Inc.)
The KOR potency studies used the cAMP Hunterâ„¢ assay with cloned human mu, delta and kappa opioid receptors. In addition, in studies conducted in collaboration with Charles Chavkin, Ph.D., Allan and Phyllis Treuer Endowed Chair of Pain Research and Professor, Department of Pharmacology, at the University of Washington Health Sciences Center, Seattle, WA, pretreatment with JT-09 or with difelikefalin (which is being developed as Korsuvaâ„¢ by Cara Therapeutics, Inc.) were observed to be equally potent in reducing scratching and grooming bouts when injected subcutaneously (0.3 mg/kg) in a 5'-guanidinonaltrindole (5'-GNTI) itch-induced mouse model.
"Pilot pharmacokinetic studies in rats previously indicated that subcutaneous placement of ProNeura implants containing JT-09 could deliver potentially therapeutic concentrations of this KOR agonist for up to six months or longer," said Kate Beebe DeVarney, Ph.D., President and Chief Operating Officer of Titan.
Dr. Beebe DeVarney continued, "These additional early positive data provide strong support for us to move forward with our planned non-clinical proof-of-concept study of JT-09 ProNeura implants in this animal itch model. This is an important next step for Titan towards developing a new treatment modality for moderate-to-severe chronic pruritus that is effective, patient-friendly and convenient."
About Chronic Pruritus
Chronic pruritus is an unpleasant sensation resulting in a need to scratch that lasts more than 6 weeks. It is a prevalent and bothersome symptom associated with both cutaneous and systemic conditions. Due to its complex pathogenesis and numerous contributing factors, effective treatment of chronic pruritus therapy remains challenging.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is a development-stage biotechnology company developing proprietary therapeutics using its clinically proven ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.
https://www.titanpharm.com/news/press-releases/detail/255/positive-early-study-results-help-pave-wave-for-titan
TTNP Nice News! Alert! Alert! Strong Premarket!
Wallstreetbets said TTNP is The Next...[/b
Wallstreetbets said TTNP is The Next...
SLRX sounds of war According wallstreetbets...
SLRX massive short squeeze for The Next week! Wallstreetbets pumping this stock!
SLRX massive short squeeze for The Next week! Wallstreetbets pumping this stock!
Wallstreetbets pump TTNP for The Next week. Only 9MM float with Citadel and Sabby has put options.
Grabbed more shares SLRX In Q1 2021 presents results about Ewing Sarcoma phase I study.
SLRX According Chart, Golden Cross for The Next week...
Chart: https://schrts.co/RrjHkkaM
SLRX $1.12
AEZS for tomorrow...
SLRX Golden Cross...
AEZS alert! Alert! Mega Breakout!
TTNP Biden moving to nix Trump plan on opioid-treatment prescriptions
https://www.washingtonpost.com/health/2021/01/25/biden-buprenorphine-waiver/
AEZS Breakout in AH
SLRX Next Golden Cross according Chart:
https://schrts.co/ECWwEJpN
SLRX Breakout!
SLRX Breakout!
SLRX Low float... Only 19.8MM...
SLRX alert! Alert! Breakout! Chart:
https://schrts.co/rYuEfvfn
SLRX I bought more for 2021
Reload TTNP for 2021
TTNP 8MM outstanding shares and 0 authorized shares...
SLRX Breakout...
SLRX Now or never... Low float
SLRX alert! Alert! Low float
SLRX Low float...
SLRX breakout Chart according FULL STO
https://schrts.co/YDuqxqeP
TTNP Low float for short squeeze...
SLRX 19MM float...